Editorial: Signalling pathways in anti-cancer drug resistance

Current Medicinal Chemistry

Volumn 21, Issue 26, 2014, Pages 3007-3008

  Chen, Chen ^a   Chen, Jiezhong ^a   Zhao, Kong Nan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90 INHIBITOR; LONG UNTRANSLATED RNA; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DELAYED DIAGNOSIS; DEVELOPED COUNTRY; DNA REPAIR; DRUG DETOXIFICATION; DRUG RESISTANCE; EDITORIAL; GENE EXPRESSION; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; LUNG CANCER; MULTIPLE MYELOMA; OBSERVATIONAL STUDY; PROSTATE CANCER; SURVIVAL RATE; TREATMENT FAILURE; UTERINE CERVIX CANCER; PUBLICATION; SIGNAL TRANSDUCTION;

DRUG RESISTANCE, NEOPLASM; HUMANS; PERIODICALS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 84906085263     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986732126140804160443     Document Type: Editorial

References (28)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA-Cancer J. Clin., 2011, 61(2), 69-90.
2. Holohan, C.; Van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer, 2013, 13(10), 714-726.
3. Chen, J.; Shao, R.; Zhang, X.D.; Chen, C. Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int. J. Nanomedicine, 2013, 8, 2677-2688.
4. Dean, M.; Fojo, T.; Bates, S.Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5(4), 275-284.
5. Chen, J.; Raymond, K. Nuclear receptors, bile-acid detoxification, and cholestasis. Lancet, 2006, 367(9509), 454-456.
6. Gottesman, M.M. Mechanisms of cancer drug resistance. Ann. Rev. Med., 2002, 53(1), 615-627.
7. Longley, D.; Johnston, P. Molecular mechanisms of drug resistance. J. Pathol., 2005, 205(2), 275-292.
8. Luqmani, Y. Mechanisms of drug resistance in cancer chemotherapy. Med. Prin. Pract., 2008, 14(Suppl. 1), 35-48.
9. Chen, J. Multiple signal pathways in obesity-associated cancer. Obes. Rev., 2011, 12(12), 1063-1070.
10. Cantley, L.C. The phosphoinositide 3-kinase pathway. Science, 2002, 296(5573), 1655-1657.
11. Aaronson, S.A. Growth factors and cancer. Science, 1991, 254(5035), 1146-1153.
12. Taipale, J.; Beachy, P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature, 2001, 411(6835), 349-354.
13. Sancho, E.; Batlle, E.; Clevers, H. Signalling pathways in intestinal development and cancer. Annu. Rev. Cell Dev. Biol., 2004, 20, 695-723.
14. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer, 2003, 3(1), 11-22.
15. Chen, J.; Huang, X.-F.; Qiao, L.; Katsifis, A. Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. J. Gastrointest. Oncol., 2011, 2(1), 27-33.
16. Chen, J.; Katsifis, A.; Hu, C.; Huang, X.F. Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway. Curr. Drug Discover. Technol., 2011, 8(2), 119-125.
17. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci., 2003, 94(1), 15-21.
18. Smalley, K.S.; Haass, N.K.; Brafford, P.A.; Lioni, M.; Flaherty, K.T.; Herlyn, M. Multiple signalling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther., 2006, 5(5), 1136-1144.
19. Chen, J. Targeted therapy of obesity-associated colon cancer. Transl. Gastrointest. Cancer, 2011, 1(1), 44-57.
20. Barrott, J.J.; Haystead, T.A. Hsp90, an unlikely ally in the war on cancer. FEBS J., 2013, 280(6), 1381-1396.
21. Zhang, R.; Luo, D.; Miao, R.; Bai, L.; Ge, Q.; Sessa, W.C.; Min, W. Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene, 2005, 24(24), 3954-3963.
22. Schoof, N.; von Bonin, F.; Trümper, L.; Kube, D. HSP90 is essential for Jak-STAT signalling in classical Hodgkin lymphoma cells. Cell Commun. Signal., 2009, 7, 17.
23. Semenza, G.L. HIF-1 and tumour progression: pathophysiology and therapeutics. Trends Mol. Med., 2002, 8(4), S62-S67.
24. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003, 3(10), 721-732.
25. Eddy, S.R. Non-coding RNA genes and the modern RNA world. Nat. Rev. Genet., 2001, 2(12), 919-929.
26. Mercer, T.R.; Dinger, M.E.; Mattick, J.S. Long non-coding RNAs: insights into functions. Nat. Rev. Genet., 2009, 10(3), 155-159.
27. Elfiky, A.A.; Jiang, Z. The PI3 Kinase Signalling Pathway in Prostate Cancer. Curr. Cancer Drug Targets, 2013, 13(2), 157-164.
28. Bitting, R.L.; Armstrong, A.J. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr. Relat. Cancer, 2013, 20(3), R83-R99.